Comparative Pharmacology
Head-to-head clinical analysis: JANUVIA versus NESINA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUVIA versus NESINA.
JANUVIA vs NESINA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing levels of active incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Inhibitor of dipeptidyl peptidase-4 (DPP-4), preventing inactivation of incretin hormones (GLP-1, GIP), thereby increasing insulin secretion and decreasing glucagon release in a glucose-dependent manner.
100 mg orally once daily
25 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: 12.4 hours. Clinical context: supports once-daily dosing in patients with normal renal function.
Terminal elimination half-life: 12.4–26.1 hours (mean ~21 hours); supports once-daily dosing
Renal: approximately 87% (79% unchanged sitagliptin, 16% metabolites). Fecal/biliary: 13% (metabolites and unchanged drug).
Renal: 87% (75% as unchanged drug, 12% as inactive metabolites); Fecal: <1%
Category C
Category C
DPP-4 Inhibitor
DPP-4 Inhibitor